KRAS and rectosigmoid carcinoma: Results of the present study suggest that dysregulated serum lipid profile may be implicated in KRAS mutated signaling pathways in a subset of KRAS mutated metastatic recto-sigmoid cancers, thus leading to the deduction that lipid lowering treatment may be effective in such subset of mCRC patients.